Petros pharmaceuticals announces second quarter financial results and provides corporate update; reports a 123% increase in year over year quarterly stendra® (avanafil) net sales

New york, aug. 17, 2021 /prnewswire/ -- petros pharmaceuticals, inc. ("petros" or "the company") (nasdaq: ptpi), a leading provider of therapeutics for men's health, today announced financial results for the second quarter ended june 30, 2021. second quarter highlights: completed pilot label comprehension study to initiate process for stendra prescription erectile dysfunction medication to support the process for designation as over -the-counter treatment initiated communications with the u.s. food and drug administration regarding expansions to stendra's package insert (label) stendra® net sales increased 123% during the second quarter of 2021 vs.
PTPI Ratings Summary
PTPI Quant Ranking